Indexed by Science Citation Index (SciSearch), International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate

ISSN: 1596-5996 (print); 1596-9827 (electronic)-


Home | Back Issues | Current Issue | Review manuscript | Submit manuscript

 
 

This Article

 

Abstract

 

Full-Text (PDF)

 

Table of contents

 

Comments

 

Letters

 

Comments to Editor

 

e-mail Alert

 

Sign Up

 

Research Article


Preparation, Characterisation and In Vivo Evaluation of Silybin Nanoparticles for the Treatment of Liver Fibrosis 

Chandrasekhar R Bonepally1, Sai Jyothsna Gandey1, Krishnaveni Bommineni1, Krishna Mohan Gottumukkala2 and Jithan Aukunuru3*

1Vaagdevi College of Pharmacy, Warangal, AP, 2Department of Pharmaceutical Sciences, JNTU, Hyderabad, AP, 3Mother Teresa College of Pharmacy, Hyderabad, AP, India

*For correspondence: E-mail: aukunjv@gmail.com

 Received:  17 November 2011                                         Revised accepted: 25 November 2012

 

Tropical Journal of Pharmaceutical Research, February 2013; 12(1): 1-6

http://dx.doi.org/10.4314/tjpr.v12i1.1   

Abstract

 

Purpose: To formulate and characterize nanoparticles containing silybin, and evaluate their activity against carbon tetrachloride (CCl4)-induced liver toxicity. 

Methods: Silybin nanoparticles were formulated by o/w emulsion solvent evaporation technique using poly-ε-caprolactone as polymer. Four different nanoparticle formulations (NP1, NP2, NP3 and NP4) were prepared by varying the drug/polymer ratio. The particles were characterized for particle size, drug content and in vitro drug release. The pharmacokinetics and pharmacodynamics of the silybin formulations in male Wistar rats were evaluated following i.v. administration, using silybin solution as reference. The hepatoprotective activity of the formulations was also determined in a CCl4-treated rat model.

Results: Silybin nanoparticles were successfully prepared using o/w emulsion solvent evaporation technique. The nanoparticles sustained the release of the drug both in vitro and in vivo for up to 10 days and offered better pharmacokinetic properties than the free drug itself. Intravenous nanoparticulate administration reversed serum liver enzyme levels by 95 % compared to only 50 % for the drug solution.

Conclusion: The developed silybin nanoparticles showed superior pharmacokinetic properties and hepatoprotective activity to silybin solution.

 

Keywords: Silybin, Nanoparticles, Pharmacokinetics, Pharmacodynamics, Hepatoprotective activity.

Copyright@2002-2010. Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City. All rights reserved.

Powered by Poracom E-mail: jmanager@poracom.net